Activation and Pharmacological Regulation of Inflammasomes - PubMed
- ️Sat Jan 01 2022
Review
Activation and Pharmacological Regulation of Inflammasomes
Chen Chen et al. Biomolecules. 2022.
Abstract
Inflammasomes are intracellular signaling complexes of the innate immune system, which is part of the response to exogenous pathogens or physiological aberration. The multiprotein complexes mainly consist of sensor proteins, adaptors, and pro-caspase-1. The assembly of the inflammasome upon extracellular and intracellular cues drives the activation of caspase-1, which processes pro-inflammatory cytokines IL-1β and IL-18 to maturation and gasdermin-D for pore formation, leading to pyroptosis and cytokine release. Inflammasome signaling functions in numerous infectious or sterile inflammatory diseases, including inherited autoinflammatory diseases, metabolic disorders, cardiovascular diseases, cancers, neurodegenerative disorders, and COVID-19. In this review, we summarized current ideas on the organization and activation of inflammasomes, with details on the molecular mechanisms, regulations, and interventions. The recent developments of pharmacological strategies targeting inflammasomes as disease therapeutics were also covered.
Keywords: AIM2; GSDMD; IL-1β; NLRP3; caspase; disease; inflammasome; inflammation; inhibitor; targeting.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Domain architecture of canonical inflammasome sensors. Overview and alignment of the distinct domains for sensors that initiate canonical inflammasome signaling.

Assembly of canonical inflammasomes. An organization summary for the assembly of canonical inflammasomes, comprising sensors, adaptors/ASC, and effectors/caspase-1.

Activation of the NLRP3 inflammasome. Activation of the NLRP3 inflammasome undergoes two sequential steps. The priming process (signal 1) includes the recognition of PAMPs/DAMPs through TLRs and/or sensing of TNFα through TNFR, which induces the expression of NLRP3, pro-IL-1β, and pro-IL-18 proteins via NF-κB signaling. The activation process requires a signal (signal 2) that multiple pathogenic and sterile inflammatory cues can provide. Oligomerization and activation of NLRP3 inflammasome lead to the processing of pro-caspase-1 into the mature form, which in turn processes pro-IL-1β, pro-IL-18, and GSDMD. The released N-terminal domain of GSDMD enters the membrane, forming a pore structure for releasing matured IL-1β and IL-18 into the extracellular space, inducing pyroptosis and causing inflammation.

Inflammasome-related human diseases. Canonical inflammasomes are involved in multiple inherited diseases (yellow-shaded boxes) and non-hereditary sterile inflammatory diseases (blue-shaded boxes). The highly relevant inflammasomes responsible for sterile inflammatory diseases are labeled in red.

Pharmacological targeting of the NLRP3 inflammasome mechanisms. A wide variety of small synthetic molecules, natural compounds, and antibodies have been developed to target the canonical NLRP3 inflammasome signaling components as research tools and medicines in trials and clinics. Natural, but not synthetic, products are labeled in purple.
Similar articles
-
Uncoupled pyroptosis and IL-1β secretion downstream of inflammasome signaling.
Li Y, Jiang Q. Li Y, et al. Front Immunol. 2023 Apr 6;14:1128358. doi: 10.3389/fimmu.2023.1128358. eCollection 2023. Front Immunol. 2023. PMID: 37090724 Free PMC article. Review.
-
Guo Q, Wu Y, Hou Y, Liu Y, Liu T, Zhang H, Fan C, Guan H, Li Y, Shan Z, Teng W. Guo Q, et al. Front Immunol. 2018 Jun 4;9:1197. doi: 10.3389/fimmu.2018.01197. eCollection 2018. Front Immunol. 2018. PMID: 29915579 Free PMC article.
-
Schneider KS, Groß CJ, Dreier RF, Saller BS, Mishra R, Gorka O, Heilig R, Meunier E, Dick MS, Ćiković T, Sodenkamp J, Médard G, Naumann R, Ruland J, Kuster B, Broz P, Groß O. Schneider KS, et al. Cell Rep. 2017 Dec 26;21(13):3846-3859. doi: 10.1016/j.celrep.2017.12.018. Cell Rep. 2017. PMID: 29281832 Free PMC article.
-
Lu F, Lan Z, Xin Z, He C, Guo Z, Xia X, Hu T. Lu F, et al. J Cell Physiol. 2020 Apr;235(4):3207-3221. doi: 10.1002/jcp.29268. Epub 2019 Oct 17. J Cell Physiol. 2020. PMID: 31621910 Review.
-
Wang S, Moreau F, Chadee K. Wang S, et al. PLoS Pathog. 2022 Mar 18;18(3):e1010415. doi: 10.1371/journal.ppat.1010415. eCollection 2022 Mar. PLoS Pathog. 2022. PMID: 35303042 Free PMC article.
Cited by
-
Feng Y, Li J, Mo X, Ju Q. Feng Y, et al. Front Immunol. 2024 Mar 14;15:1355455. doi: 10.3389/fimmu.2024.1355455. eCollection 2024. Front Immunol. 2024. PMID: 38550588 Free PMC article. Review.
-
Wu L, Tan Z, Su L, Dong F, Xu G, Zhang F. Wu L, et al. Front Cell Neurosci. 2024 Jan 11;17:1343842. doi: 10.3389/fncel.2023.1343842. eCollection 2023. Front Cell Neurosci. 2024. PMID: 38273974 Free PMC article.
-
Li N, Zhang L, Wang X, Zhou Y, Gong L. Li N, et al. Front Endocrinol (Lausanne). 2023 Oct 4;14:1230646. doi: 10.3389/fendo.2023.1230646. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37859981 Free PMC article. Review.
-
USP30-AS1 Suppresses Colon Cancer Cell Inflammatory Response Through NF-κB/MYBBP1A Signaling.
Wang R, Li X, Jiang Y, Zhang H, Yang S, Xie W, Xu N. Wang R, et al. Inflammation. 2024 Nov 6. doi: 10.1007/s10753-024-02170-8. Online ahead of print. Inflammation. 2024. PMID: 39503963
-
The role of NLRP3 inflammasome in inflammation-related skeletal muscle atrophy.
Liu Y, Wang D, Li T, Yang F, Li Z, Bai X, Wang Y. Liu Y, et al. Front Immunol. 2022 Nov 3;13:1035709. doi: 10.3389/fimmu.2022.1035709. eCollection 2022. Front Immunol. 2022. PMID: 36405697 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
This work was supported by the National Key Research and Development Program of China (2021YFA1301401 to P.X.) and the NSFC Projects (31725017 and 31830052 to P.X.).
LinkOut - more resources
Full Text Sources
Miscellaneous